Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Holoclar

- PMLiVE

Future gazing: What does 2015 hold for NICE?

Undermined by the CDF, the Institute is set to face a number of challenges this year

National Institute for Health and Care Excellence NICE logo

Good NICE news for Pfizer, but Dendreon drug rejected

Kidney cancer drug Inlyta backed but prostate cancer treatment Provenge is not

EU flag

Europe gains access to first stem cell drug

Chiesi's Holoclar has been given the green light for a rare eye condition

- PMLiVE

England’s medicine prices ‘too high’

New analysis finds NICE is too lenient on pharma’s price tags

National Institute for Health and Care Excellence NICE logo

NICE sets out approach to stop antimicrobial resistance

Guidelines call for formation of stewardship programmes

- PMLiVE

NICE issues fresh rejection for Celgene’s cancer drug Imnovid

Drugpricing watchdog says the treatment is too costly for NHS use

- PMLiVE

NICE consults on reducing melanoma cases

New guidance set to focus on diagnosing and managing the skin cancer  

- PMLiVE

NICE backs first ‘ultra-orphan’ drug Soliris

Final guidance backs Alexion’s treatment for very rare blood clot condition

- PMLiVE

NICE heart attack recommendation for Xarelto

Bayer drug on course for another blood clot indication in England and Wales

- PMLiVE

CDF chair regrets undermining NICE

But Prof Clark says he wholeheartedly supports the Institute

- PMLiVE

NICE backs new hepatitis C treatments

But Sovaldi faces funding delay and Olysio not backed in all indications

- PMLiVE

NICE says cost of Dendreon’s cancer vaccine is too high

Another blow as the bankrupt company goes to auction next month

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links